Display options
Cite
Albaugh MD, Ottino-Gonzalez J, Sidwell A, et al. Association of Cannabis Use During Adolescence With Neurodevelopment. JAMA Psychiatry. 2021;doi: 10.1001/jamapsychiatry.2021.1258.
Albaugh, M. D., Ottino-Gonzalez, J., Sidwell, A., Lepage, C., Juliano, A., Owens, M. M., Chaarani, B., Spechler, P., Fontaine, N., Rioux, P., Lewis, L., Jeon, S., Evans, A., D'Souza, D., Radhakrishnan, R., Banaschewski, T., Bokde, A. L. W., Quinlan, E. B., Conrod, P., Desrivières, S., Flor, H., Grigis, A., Gowland, P., Heinz, A., Ittermann, B., Martinot, J. L., Paillère Martinot, M. L., Nees, F., Papadopoulos Orfanos, D., Paus, T., Poustka, L., Millenet, S., Fröhner, J. H., Smolka, M. N., Walter, H., Whelan, R., Schumann, G., Potter, A., Garavan, H. (2021). Association of Cannabis Use During Adolescence With Neurodevelopment. JAMA psychiatry, . https://doi.org/10.1001/jamapsychiatry.2021.1258
Albaugh, Matthew D, et al. "Association of Cannabis Use During Adolescence With Neurodevelopment." JAMA psychiatry vol. (2021). doi: https://doi.org/10.1001/jamapsychiatry.2021.1258
Albaugh MD, Ottino-Gonzalez J, Sidwell A, Lepage C, Juliano A, Owens MM, Chaarani B, Spechler P, Fontaine N, Rioux P, Lewis L, Jeon S, Evans A, D'Souza D, Radhakrishnan R, Banaschewski T, Bokde ALW, Quinlan EB, Conrod P, Desrivières S, Flor H, Grigis A, Gowland P, Heinz A, Ittermann B, Martinot JL, Paillère Martinot ML, Nees F, Papadopoulos Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Smolka MN, Walter H, Whelan R, Schumann G, Potter A, Garavan H. Association of Cannabis Use During Adolescence With Neurodevelopment. JAMA Psychiatry. 2021 Jun 16; doi: 10.1001/jamapsychiatry.2021.1258. Epub 2021 Jun 16. PMID: 34132750; PMCID: PMC8209561.
Copy Download .nbib Format: NLM
Share it on

JAMA Psychiatry. 2021 Jun 16; doi: 10.1001/jamapsychiatry.2021.1258. Epub 2021 Jun 16.

Association of Cannabis Use During Adolescence With Neurodevelopment.

JAMA psychiatry

Matthew D Albaugh, Jonatan Ottino-Gonzalez, Amanda Sidwell, Claude Lepage, Anthony Juliano, Max M Owens, Bader Chaarani, Philip Spechler, Nicholas Fontaine, Pierre Rioux, Lindsay Lewis, Seun Jeon, Alan Evans, Deepak D'Souza, Rajiv Radhakrishnan, Tobias Banaschewski, Arun L W Bokde, Erin Burke Quinlan, Patricia Conrod, Sylvane Desrivières, Herta Flor, Antoine Grigis, Penny Gowland, Andreas Heinz, Bernd Ittermann, Jean-Luc Martinot, Marie-Laure Paillère Martinot, Frauke Nees, Dimitri Papadopoulos Orfanos, Tomáš Paus, Luise Poustka, Sabina Millenet, Juliane H Fröhner, Michael N Smolka, Henrik Walter, Robert Whelan, Gunter Schumann, Alexandra Potter, Hugh Garavan,

Affiliations

  1. Department of Psychiatry, University of Vermont Larner College of Medicine, Burlington.
  2. McConnell Brain Imaging Centre, McGill University, Montreal, Quebec, Canada.
  3. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
  4. Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  5. Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
  6. Centre for Population Neuroscience and Precision Medicine, Institute of Psychiatry, Psychology, and Neuroscience, Social, Genetic & Developmental Psychiatry Centre, King's College London, London, United Kingdom.
  7. Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada.
  8. Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  9. Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany.
  10. NeuroSpin, Commissariat à l'Energie Atomique, Université Paris-Saclay, Gif-sur-Yvette, France.
  11. Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom.
  12. Department of Psychiatry and Psychotherapy Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  13. corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  14. Berlin Institute of Health, Berlin, Germany.
  15. Physikalisch-Technische Bundesanstalt, Berlin, Germany.
  16. Institut National de la Santé et de la Recherche Médicale U A10 "Trajectoires développementales en psychiatrie" Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-sur-Yvette, France.
  17. Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie," Paris, France.
  18. Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Paris, France.
  19. AP-HP Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France.
  20. Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, Kiel, Germany.
  21. Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada.
  22. Department of Psychology, University of Toronto, Toronto, Ontario, Canada.
  23. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  24. Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, Göttingen, Germany.
  25. Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.
  26. School of Psychology and Global Brain Health Institute, Trinity College Dublin, Ireland.
  27. Centre for Population Neuroscience and Precision Medicine Research Group, Department of Psychiatry and Psychotherapy, Campus Charite Mitte, Humboldt University, Berlin, Germany.
  28. Leibniz Institute for Neurobiology, Magdeburg, Germany.
  29. Institute for Science and Technology of Brain-inspired Intelligence, Fudan University, Shanghai, PR China.

PMID: 34132750 PMCID: PMC8209561 DOI: 10.1001/jamapsychiatry.2021.1258

Abstract

IMPORTANCE: Animal studies have shown that the adolescent brain is sensitive to disruptions in endocannabinoid signaling, resulting in altered neurodevelopment and lasting behavioral effects. However, few studies have investigated ties between cannabis use and adolescent brain development in humans.

OBJECTIVE: To examine the degree to which magnetic resonance (MR) imaging-assessed cerebral cortical thickness development is associated with cannabis use in a longitudinal sample of adolescents.

DESIGN, SETTING, AND PARTICIPANTS: Data were obtained from the community-based IMAGEN cohort study, conducted across 8 European sites. Baseline data used in the present study were acquired from March 1, 2008, to December 31, 2011, and follow-up data were acquired from January 1, 2013, to December 31, 2016. A total of 799 IMAGEN participants were identified who reported being cannabis naive at study baseline and had behavioral and neuroimaging data available at baseline and 5-year follow-up. Statistical analysis was performed from October 1, 2019, to August 31, 2020.

MAIN OUTCOMES AND MEASURES: Cannabis use was assessed at baseline and 5-year follow-up with the European School Survey Project on Alcohol and Other Drugs. Anatomical MR images were acquired with a 3-dimensional T1-weighted magnetization prepared gradient echo sequence. Quality-controlled native MR images were processed through the CIVET pipeline, version 2.1.0.

RESULTS: The study evaluated 1598 MR images from 799 participants (450 female participants [56.3%]; mean [SD] age, 14.4 [0.4] years at baseline and 19.0 [0.7] years at follow-up). At 5-year follow-up, cannabis use (from 0 to >40 uses) was negatively associated with thickness in left prefrontal (peak: t785 = -4.87, cluster size = 1558 vertices; P = 1.10 × 10-6, random field theory cluster corrected) and right prefrontal (peak: t785 = -4.27, cluster size = 1551 vertices; P = 2.81 × 10-5, random field theory cluster corrected) cortices. There were no significant associations between lifetime cannabis use at 5-year follow-up and baseline cortical thickness, suggesting that the observed neuroanatomical differences did not precede initiation of cannabis use. Longitudinal analysis revealed that age-related cortical thinning was qualified by cannabis use in a dose-dependent fashion such that greater use, from baseline to follow-up, was associated with increased thinning in left prefrontal (peak: t815.27 = -4.24, cluster size = 3643 vertices; P = 2.28 × 10-8, random field theory cluster corrected) and right prefrontal (peak: t813.30 = -4.71, cluster size = 2675 vertices; P = 3.72 × 10-8, random field theory cluster corrected) cortices. The spatial pattern of cannabis-related thinning was associated with age-related thinning in this sample (r = 0.540; P < .001), and a positron emission tomography-assessed cannabinoid 1 receptor-binding map derived from a separate sample of participants (r = -0.189; P < .001). Analysis revealed that thinning in right prefrontal cortices, from baseline to follow-up, was associated with attentional impulsiveness at follow-up.

CONCLUSIONS AND RELEVANCE: Results suggest that cannabis use during adolescence is associated with altered neurodevelopment, particularly in cortices rich in cannabinoid 1 receptors and undergoing the greatest age-related thickness change in middle to late adolescence.

References

  1. Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20750-20759 - PubMed
  2. Alcohol Alcohol. 2007 Nov-Dec;42(6):582-7 - PubMed
  3. Data Brief. 2015 Nov 10;5:929-38 - PubMed
  4. Addict Biol. 2009 Sep;14(4):457-68 - PubMed
  5. Am J Psychiatry. 2019 Feb 1;176(2):98-106 - PubMed
  6. PLoS One. 2012;7(2):e31731 - PubMed
  7. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan;1(1):60-67 - PubMed
  8. J Neurosci. 2019 Mar 6;39(10):1817-1827 - PubMed
  9. J Stud Alcohol Drugs. 2014 Sep;75(5):729-43 - PubMed
  10. Neuroimage. 2004;23 Suppl 1:S189-95 - PubMed
  11. Neurobiol Dis. 2014 Mar;63:35-47 - PubMed
  12. Arch Intern Med. 1998 Sep 14;158(16):1789-95 - PubMed
  13. Brain Res. 2017 Jan 1;1654(Pt B):157-164 - PubMed
  14. Science. 2007 May 25;316(5828):1212-6 - PubMed
  15. Trends Pharmacol Sci. 2007 Feb;28(2):83-92 - PubMed
  16. Neuropsychopharmacology. 2018 Jan;43(1):21-33 - PubMed
  17. Int J Neuropsychopharmacol. 2011 Feb;14(1):43-51 - PubMed
  18. Neuroimage. 2016 Jan 15;125:267-279 - PubMed
  19. Am J Psychiatry. 2014 Apr;171(4):416-25 - PubMed
  20. Behav Brain Res. 2011 Jun 20;220(1):164-72 - PubMed
  21. Neuropsychopharmacology. 2008 Oct;33(11):2760-71 - PubMed
  22. J Neurosci. 2017 Mar 22;37(12):3402-3412 - PubMed
  23. Psychopharmacology (Berl). 2013 Feb;225(4):781-90 - PubMed
  24. Front Psychol. 2010 Dec 14;1:225 - PubMed
  25. JAMA Psychiatry. 2015 Oct;72(10):1002-11 - PubMed
  26. J Psychopharmacol. 2006 Sep;20(5):611-21 - PubMed
  27. Biol Psychiatry. 2016 Apr 1;79(7):578-85 - PubMed
  28. J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):171-80 - PubMed
  29. Drug Alcohol Depend. 1995 Nov;40(1):9-15 - PubMed
  30. Neurotox Res. 2009 May;15(4):291-302 - PubMed
  31. Neuropharmacology. 2012 Apr;62(5-6):1975-84 - PubMed
  32. Alcohol Clin Exp Res. 1998 Nov;22(8):1842-9 - PubMed
  33. Dev Cogn Neurosci. 2018 Oct;33:129-148 - PubMed
  34. Mol Psychiatry. 2019 Apr;24(4):588-600 - PubMed
  35. Am J Psychiatry. 2011 Feb;168(2):143-51 - PubMed
  36. J Neurosci. 2015 Jan 28;35(4):1505-12 - PubMed
  37. Health Educ Behav. 1997 Dec;24(6):746-58 - PubMed
  38. J Dual Diagn. 2020 Jan-Mar;16(1):83-105 - PubMed
  39. Dev Cogn Neurosci. 2015 Dec;16:101-109 - PubMed
  40. J Clin Psychol. 1995 Nov;51(6):768-74 - PubMed
  41. Psychiatry Res. 2010 May 30;182(2):152-9 - PubMed
  42. JAMA Psychiatry. 2020 Feb 1;77(2):165-171 - PubMed
  43. Cereb Cortex. 2017 Feb 1;27(2):1472-1481 - PubMed
  44. Front Neuroinform. 2014 May 21;8:54 - PubMed
  45. Cereb Cortex. 2014 Nov;24(11):2941-50 - PubMed
  46. Trends Cogn Sci. 2013 Dec;17(12):648-65 - PubMed

Publication Types